FMP30 Donor Stool

Phase 1Small molecule

FMP30 Donor Stool is one of 42 small molecule programs targeting Relapsing-Remitting Multiple Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsing-Remitting Multiple SclerosisActive, not recruiting

Relapsing-Remitting Multiple SclerosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

107 competitors in Relapsing-Remitting Multiple Sclerosis

#DrugCompanyPhaseTrials

Copaxone

Teva

Phase 3

6 2

Betaseron

Bayer

Phase 3

4 3

Aubagio

Sanofi

Phase 3

1 4

Rituxan

Avonex

4 6

Fluzone

Robitussin

Campath

GGenzyme, a Sanofi Company

Phase 3

1 9

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 10

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Relapsing-Remitting Multiple Sclerosis1 trial

Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis

Terminated·JJeffrey Gelfand·Phase 1·NCT03594487·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FMP30 Donor Stool. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FMP30 Donor Stool compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FMP30 Donor Stool. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jeffrey Gelfand company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: JJeffrey Gelfand

FMP30 Donor Stool

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Relapsing-Remitting Multiple Sclerosis1 trial

References

Drug Info

Quick Facts

Related News